An evaluation of clinical response to piperazine oestrone sulphate ('Harmogen') in menopausal patients

Aylward, Mansel, Holly, F. and Parker, R. J. 1974. An evaluation of clinical response to piperazine oestrone sulphate ('Harmogen') in menopausal patients. Current Medical Research and Opinion 2 (7) , pp. 417-423. 10.1185/03007997409112658

Full text not available from this repository.

Abstract

The results are reported of a controlled, double-blind, crossover trial of piperazine oestrone sulphate (‘Harmogen’) compared with ethinyl oestradiol and placebo in menopausal patients with features of endogenous oestrogen withdrawal. The oestro-genicity of both active substances was well substantiated by vaginal epithelial maturation indices. Piperazine oestrone sulphate was superior to ethinyl oestradiol, at the dosage levels used, in producing a more pronounced relief of menopausal symptoms without any notable adverse effects. The incidence of side-effects was greater during treatment with ethinyl oestradiol. Piperazine oestrone sulphate is considered to be at least as effective an oestrogenic substance as ethinyl oestradiol and worthy of further therapeutic evaluation. Read More: http://informahealthcare.com/doi/abs/10.1185/03007997409112658

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	menopause, oestrogenic substances, conjugated, piperazine oestrone sulphate, ethinyl oestradiol
Publisher:	Informa Healthcare
ISSN:	0300-7995
Last Modified:	04 Jun 2017 04:19
URI:	https://orca.cardiff.ac.uk/id/eprint/36690

Citation Data

Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item